Cashu
Vanda Pharmaceuticals Faces FDA Rejection of HETLIOZ® Amid Ongoing Regulatory Dispute
about 1 month ago
Stocks
Health Care
vnda
Vanda Pharmaceuticals
NASDAQ: VNDA
+2.41 (+41.84%)
8.17
USD
At close at Feb 23, 21:38 UTC
Latest Vanda Pharmaceuticals News
benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
about 7 hours ago
benzinga.com
ImmunityBio Posts Upbeat Q4 Earnings, Joins Arcellx, Vanda Pharmaceuticals And Other Big Stocks Moving Higher On Monday
about 9 hours ago
benzinga.com
Vanda Pharmaceuticals FDA Approval Dawns A New Era For Bipolar And Schizophrenia Treatment
about 10 hours ago
benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
about 12 hours ago
benzinga.com
Analyst Expectations For Vanda Pharmaceuticals's Future
about 12 hours ago
benzinga.com
Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
about 2 months ago
benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
about 2 months ago
prnewswire.com
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ Supplemental New Drug Application for Jet Lag Disorder
about 2 months ago
benzinga.com
FDA Approves Vanda Pharma Motion Sickness Drug, Fuels Upside
about 2 months ago
benzinga.com
S&P 500 Falls For Fourth Session But Records Gains In 2025: Investor Sentiment Declines, Fear & Greed Index Remains In 'Neutral Zone
about 2 months ago
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.